USP7 inhibition destabilizes MDM2, resulting in increased levels of TP53, and recently a number of USP7-specific inhibitors were generated that effectively targeted various human cancer cells presumably in a TP53-dependent manner (Gavory et al., 2018; Kategaya et al., 2017; Turnbull et al., 2017). This evidence concerns the gene TP53 and cancer.